Sign In to Follow Application
View All Documents & Correspondence
View All Documents & Correspondence
Herbal Microbicide Formulation For Preventing Hiv
Abstract: The present invention relates to an aqueous gel formulation and its method of preparation using combination of four or five medicinal plants for preventing sexually transmitted HIV-1. The gel formulation comprises 50% aqueous ethanolic extracts of medicinal plants namely Terminalia chebula, Phyllanthus emblica, Lagerstroemia speciosa, Acacia catechu and/or Aegle marmelos. The invention provides an herbal formulation useful as a vaginal/rectal microbicide gel. These herbal formulations showed potent in vitro anti-HIV-1 activity using reporter-gene based cell lines (TZM-bl) as well as human peripheral blood lymphocytes. These formulations also inhibited HIV-1 reverse transcriptase, integrase and protease activities suggesting that these may be working at multiple steps/stages of HIV life cycle and thus may be a valuable tool for alternative therapy.
Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence
Notices, Deadlines & Correspondence
Patent Information
Application #
Filing Date
03 February 2017
Publication Number
32/2018
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
ipr@puthrans.com
Parent Application
Patent Number
Legal Status
Grant Date
2024-03-13
Renewal Date
Applicants
HLL LIFECARE LIMITED
HLL Bhavan
Mahilamandiram Road, Poojappura
Thiruvananthapuram - 695 012
Kerala, India.
NATIONAL INSTITUTE OF IMMUNOLOGY
Aruna Asaf Ali Marg, New Delhi-110067, India
Inventors
1. Dr. Suja Kizhiyedath Polachira
HLL Lifecare Limited, Corporate R&D Centre, Akkulam, Sreekariyam (PO), Thiruvananthapuram - 695017, Kerala, India.
2. Reshmi Nair Rajagopal Jayalekha
HLL Lifecare Limited, Corporate R&D Centre, Akkulam, Sreekariyam (PO), Thiruvananthapuram - 695017, Kerala, India.
3. Dr. Satish Kumar Gupta
National Institute of Immunology,
Aruna Asaf Ali Marg,
New Delhi-110067, India.
4. Dr. Nripendra Nath Mishra
National Institute of Immunology,
Aruna Asaf Ali Marg,
New Delhi-110067, India.
5. Mrs. Aakanksha Agarwal
National Institute of Immunology,
Aruna Asaf Ali Marg,
New Delhi-110067, India.
Specification
Claims:Attached separetely , Description:Attached separetely
Documents
Orders
| Section | Controller | Decision Date |
|---|---|---|
| 15 & 43 | SARAVANA RAM PRASAD V G | 2022-12-05 |
| 15 & 43 | SARAVANA RAM PRASAD V G | 2024-03-13 |
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | PROOF OF RIGHT [03-02-2017(online)].pdf | 2017-02-03 |
| 2 | Power of Attorney [03-02-2017(online)].pdf | 2017-02-03 |
| 3 | Form 5 [03-02-2017(online)].pdf | 2017-02-03 |
| 4 | Form 3 [03-02-2017(online)].pdf | 2017-02-03 |
| 5 | Drawing [03-02-2017(online)].pdf | 2017-02-03 |
| 6 | Description(Complete) [03-02-2017(online)].pdf_104.pdf | 2017-02-03 |
| 7 | Description(Complete) [03-02-2017(online)].pdf | 2017-02-03 |
| 8 | Correspondence by Agent_Proof of Right,Power of Attorney_15-02-2017.pdf | 2017-02-15 |
| 9 | 201741004017-CERTIFIED COPIES TRANSMISSION TO IB [23-02-2018(online)].pdf | 2018-02-23 |
| 10 | 201741004017-FORM 18 [03-08-2018(online)].pdf | 2018-08-03 |
| 11 | 201741004017-FER.pdf | 2021-10-17 |
| 12 | 201741004017-Retyped Pages under Rule 14(1) [14-01-2022(online)].pdf | 2022-01-14 |
| 13 | 201741004017-OTHERS [14-01-2022(online)].pdf | 2022-01-14 |
| 14 | 201741004017-FORM 3 [14-01-2022(online)].pdf | 2022-01-14 |
| 15 | 201741004017-FER_SER_REPLY [14-01-2022(online)].pdf | 2022-01-14 |
| 16 | 201741004017-CLAIMS [14-01-2022(online)].pdf | 2022-01-14 |
| 17 | 201741004017-2. Marked Copy under Rule 14(2) [14-01-2022(online)].pdf | 2022-01-14 |
| 18 | 201741004017-US(14)-HearingNotice-(HearingDate-17-11-2022).pdf | 2022-10-19 |
| 19 | 201741004017-FORM-26 [14-11-2022(online)].pdf | 2022-11-14 |
| 20 | 201741004017-Correspondence to notify the Controller [14-11-2022(online)].pdf | 2022-11-14 |
| 21 | 201741004017-Annexure [14-11-2022(online)].pdf | 2022-11-14 |
| 22 | 201741004017-FORM 3 [16-11-2022(online)].pdf | 2022-11-16 |
| 23 | 201741004017-Correspondence_Power of Attorney_22-11-2022.pdf | 2022-11-22 |
| 24 | 201741004017-Written submissions and relevant documents [30-11-2022(online)].pdf | 2022-11-30 |
| 25 | 201741004017-Retyped Pages under Rule 14(1) [30-11-2022(online)].pdf | 2022-11-30 |
| 26 | 201741004017-Annexure [30-11-2022(online)].pdf | 2022-11-30 |
| 27 | 201741004017-2. Marked Copy under Rule 14(2) [30-11-2022(online)].pdf | 2022-11-30 |
| 28 | 201741004017-Response to office action [18-01-2023(online)].pdf | 2023-01-18 |
| 29 | 201741004017-Correspondence_By Agent_30-01-2023.pdf | 2023-01-30 |
| 30 | 201741004017-NBA Approval Submission [23-12-2023(online)].pdf | 2023-12-23 |
| 31 | 201741004017-PatentCertificate13-03-2024.pdf | 2024-03-13 |
| 32 | 201741004017-IntimationOfGrant13-03-2024.pdf | 2024-03-13 |
| 33 | 201741004017-RELEVANT DOCUMENTS [05-02-2025(online)].pdf | 2025-02-05 |
| 34 | 201741004017-POWER OF AUTHORITY [05-02-2025(online)].pdf | 2025-02-05 |
| 35 | 201741004017-FORM-15 [05-02-2025(online)].pdf | 2025-02-05 |
| 36 | 201741004017-RELEVANT DOCUMENTS [20-06-2025(online)].pdf | 2025-06-20 |
Search Strategy
| 1 | Searchstrategy4017E_13-07-2021.pdf |